Form 4: TransMedics Group Director David Weill Sells 1,193 Shares
SEC Form 4 Filing
Director David Weill of TransMedics Group, Inc. sold 1,193 shares of common stock on May 29, 2024, at a price of $141.65 per share.
Summary
- On May 29, 2024, David Weill, a director of TransMedics Group, Inc., sold 1,193 shares of the company's common stock.
- The sale price was $141.65 per share.
- Following the transaction, Weill directly owns 10,732 shares of TransMedics Group, Inc.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of a director's stock sale. The impact depends on the context and reasons behind the sale.
Negatives
- A director selling shares could be perceived negatively by some investors.
Risks
- Director share sales can sometimes signal a lack of confidence in the company's future performance, although this is not always the case.
Industry Context
This is a routine disclosure of an insider transaction. It's important to monitor insider activity in conjunction with overall company performance and industry trends.
Stakeholder Impact
- The sale could have a minor negative impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of the transaction: David Weill sold 1,193 shares of TransMedics Group, Inc. |
| 05/31/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.